Abstract
There is a strong need for new antimitotic drugs that overcome the limitations of the currently used antitubulin compounds, mainly neurotoxicity and the development of resistance. One of the most promising new targets is kinesin spindle protein (KSP, also known as Eg5), which contributes to the formation of mitotic spindle during cell division and has not been reported to play any other cellular role so far. This review covers KSP inhibitors binding at the allosteric, induced-fit L5 site reported between 2008 and December 2013. Among them, main groups include dihydropyrimidines, STLC derivatives, quinazoline-based compounds and pyrrole/ pyrazole and related agents. Structure-activity relationships are described, as well as the synthesis of representative compounds. They are remarkably selective for KSP and produce G2/M mitotic arrest accompanied by a characteristic monoastral cellular phenotype. Some of them have entered clinical trials, the most advanced being in Phase II. Therefore, KSP inhibitors show great potential as future clinical antimitotic agents, especially due to their activity in taxane-resistant tumors.
Keywords: Antimitotic, Antitumor, Inhibitors, Kinesin spindle protein, Structure-activity relationships, Synthesis.
Current Topics in Medicinal Chemistry
Title:KSP Inhibitors as Antimitotic Agents
Volume: 14 Issue: 20
Author(s): Concepcion Perez-Melero
Affiliation:
Keywords: Antimitotic, Antitumor, Inhibitors, Kinesin spindle protein, Structure-activity relationships, Synthesis.
Abstract: There is a strong need for new antimitotic drugs that overcome the limitations of the currently used antitubulin compounds, mainly neurotoxicity and the development of resistance. One of the most promising new targets is kinesin spindle protein (KSP, also known as Eg5), which contributes to the formation of mitotic spindle during cell division and has not been reported to play any other cellular role so far. This review covers KSP inhibitors binding at the allosteric, induced-fit L5 site reported between 2008 and December 2013. Among them, main groups include dihydropyrimidines, STLC derivatives, quinazoline-based compounds and pyrrole/ pyrazole and related agents. Structure-activity relationships are described, as well as the synthesis of representative compounds. They are remarkably selective for KSP and produce G2/M mitotic arrest accompanied by a characteristic monoastral cellular phenotype. Some of them have entered clinical trials, the most advanced being in Phase II. Therefore, KSP inhibitors show great potential as future clinical antimitotic agents, especially due to their activity in taxane-resistant tumors.
Export Options
About this article
Cite this article as:
Perez-Melero Concepcion, KSP Inhibitors as Antimitotic Agents, Current Topics in Medicinal Chemistry 2014; 14 (20) . https://dx.doi.org/10.2174/1568026614666141130095532
DOI https://dx.doi.org/10.2174/1568026614666141130095532 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Progress in the Development of Quinoline Derivatives for the Exploitation of Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Druggability of Mortalin for Cancer and Neuro-Degenerative Disorders
Current Pharmaceutical Design The HOX Gene Network as a Potential Target for Cancer Therapy
Current Cancer Therapy Reviews Poly(Ethylene Glycol) Amphiphilic Copolymer for Anticancer Drugs Delivery
Anti-Cancer Agents in Medicinal Chemistry Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry Molecular Biological Roles of Ursolic Acid in the Treatment of Human Diseases
Current Bioactive Compounds Nutritional Targeting of Cyclooxygenase-2 for Colon Cancer Prevention
Inflammation & Allergy - Drug Targets (Discontinued) Thymidine Phosphorylase Over-Expression in Oral Squamous Carcinoma Tissue as a Potential Target of Capecitabine
Letters in Drug Design & Discovery Radiogenetic Therapy: Strategies to Overcome Tumor Resistance
Current Pharmaceutical Design Engineered Biosynthesis of Medicinally Important Plant Natural Products in Microorganisms
Current Topics in Medicinal Chemistry Downstream Carcinogenesis Signaling Pathways by Green Tea Polyphenols: A Translational Perspective of Chemoprevention and Treatment for Cancers
Current Drug Metabolism Molecular Recognition at Purine and Pyrimidine Nucleotide (P2) Receptors
Current Topics in Medicinal Chemistry Developments of Polo-like Kinase 1 (Plk1) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Prostatic Tumor Stroma: A Key Player in Cancer Progression
Current Cancer Drug Targets Molecular Link Mechanisms between Inflammation and Cancer
Current Pharmaceutical Design Chondroitin Sulfate Glycosaminoglycans for CNS Homeostasis-Implications for Material Design
Current Medicinal Chemistry Targeting Human Telomerase by Antisense Oligonucleotides and Ribozymes: An Update
Medicinal Chemistry Reviews - Online (Discontinued) Biological Rationales and Clinical Applications of Temperature Controlled Hyperthermia - Implications for Multimodal Cancer Treatments
Current Medicinal Chemistry Thinking Outside the ‘Block’: Alternative Polymer Compositions for Micellar Drug Delivery
Current Topics in Medicinal Chemistry A Comprehensive Review on the Genetic Regulation of Cisplatin-induced Nephrotoxicity
Current Genomics